Xianzhong Cheng

Nanjing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 19 publications

TCGA molecular subtypes in endometriosis-associated ovarian cancer: a systematic review and meta-analysis.

TCGA molecular subtypes in endometriosis-associated ovarian cancer: a systematic review and meta-analysis.

Journal: Annals of medicine

Published: November 12, 2025

Exploring the optimal cutoff point and genomic characteristics for PARP inhibitor maintenance therapy in early recurrence of ovarian cancer.

Exploring the optimal cutoff point and genomic characteristics for PARP inhibitor maintenance therapy in early recurrence of ovarian cancer.

Journal: Journal of ovarian research

Published: November 02, 2025

Efficacy and Safety of Multivisceral Resection for Ovarian Cancer: A Comparative Study of Gynecologic Oncologists and Multidisciplinary Surgeons.

Efficacy and Safety of Multivisceral Resection for Ovarian Cancer: A Comparative Study of Gynecologic Oncologists and Multidisciplinary Surgeons.

Journal: Cancer medicine

Published: August 30, 2025

Niraparib combined with anlotinib after PARPi resistance in ovarian cancer: A single-center retrospective study from China.

Niraparib combined with anlotinib after PARPi resistance in ovarian cancer: A single-center retrospective study from China.

Journal: European journal of obstetrics, gynecology, and reproductive biology

Published: August 16, 2025

Investigating the diversity of intratumoral microbiota in high-grade serous ovarian cancer with varying platinum sensitivity.

Investigating the diversity of intratumoral microbiota in high-grade serous ovarian cancer with varying platinum sensitivity.

Journal: Frontiers in cellular and infection microbiology

Published: June 24, 2025

Infective endocarditis after splenectomy for ovarian cancer: a case report.

Infective endocarditis after splenectomy for ovarian cancer: a case report.

Journal: BMC surgery

Published: May 21, 2025

Prognostic Factors and Role of Pelvic Lymphadenectomy in Patients with Uterine Sarcoma: A Multi-Center Population-Based Cohort Study.

Prognostic Factors and Role of Pelvic Lymphadenectomy in Patients with Uterine Sarcoma: A Multi-Center Population-Based Cohort Study.

Journal: International journal of women's health

Published: April 26, 2025

Real-world experience and prognostic factors in ovarian carcinosarcoma: a single-center retrospective study from China.

Real-world experience and prognostic factors in ovarian carcinosarcoma: a single-center retrospective study from China.

Journal: Frontiers in oncology

Published: February 15, 2025

Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report.

Platinum Resistance After PARPi Resistance in a gBRCAmt Recurrent Ovarian Cancer Patient: a Case Report.

Journal: Reproductive sciences (Thousand Oaks, Calif.)

Published: May 04, 2022

High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis.

High Serpin Family A Member 10 Expression Confers Platinum Sensitivity and Is Associated With Survival Benefit in High-Grade Serous Ovarian Cancer: Based on Quantitative Proteomic Analysis.

Journal: Frontiers in oncology

Published: September 28, 2021

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China.

Journal: Frontiers in oncology

Published: July 24, 2021

Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor.

Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor.

Journal: Frontiers in oncology

Published: June 13, 2021

Showing 1-12 of 19

Last Updated: 09/26/2026